he U.S. FDA has granted accelerated approval to AKEEGA® (niraparib and abiraterone acetate), a dual-action precision therapy for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). The combination treatment, which includes a PARP inhibitor, is the first of its kind to target this specific genetic mutation. Clinical trials demonstrated that the drug combination significantly reduced the risk of disease progression or death by 54% compared to the standard of care, marking a major breakthrough in personalized cancer medicine.
Source: Johnson & Johnson Innovative Medicine







Leave a Reply